Granules India Limited (NSE:GRANULES)
845.00
+19.30 (2.34%)
Aug 5, 2026, 3:30 PM IST
Granules India Revenue
Granules India had revenue of 14.77B INR in the quarter ending June 30, 2026, with 22.04% growth. This brings the company's revenue in the last twelve months to 56.32B, up 24.83% year-over-year. In the fiscal year ending March 31, 2026, Granules India had annual revenue of 53.66B with 19.73% growth.
Revenue (ttm)
56.32B
Revenue Growth
+24.83%
P/S Ratio
3.71
Revenue / Employee
13.08M
Employees
4,306
Market Cap
209.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 53.66B | 8.84B | 19.73% |
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 92.05B |
| Emcure Pharmaceuticals | 92.04B |
| Alembic Pharmaceuticals | 73.45B |
| Gland Pharma | 64.31B |
| Akums Drugs and Pharmaceuticals | 43.61B |
| NATCO Pharma | 40.78B |
| Wockhardt | 34.62B |
| Eris Lifesciences | 32.12B |
Granules India News
- 15 days ago - Granules India Transcript: Q1 26/27 - Transcripts
- 15 days ago - Granules India Quarterly report: Q1 2027 - Filings
- 15 days ago - Granules India Slides: Q1 2027 - Filings
- 15 days ago - Granules India's first-quarter profit surges as margins improve - Reuters
- 4 weeks ago - Granules India secures sole First-to-File status for generic drug - The Times of India
- 4 weeks ago - Granules India shares gain 2% after company secures Sole First-to-File status for Sodium Oxybate ANDA in US - Business Upturn
- 4 weeks ago - Granules India secures sole first-to-file ANDA status for sodium oxybate - Business Upturn
- 2 months ago - Granules India subsidiary receives USFDA EIR for Chantilly facility - Business Upturn